Advertise on podcast: PETRI DISH PERSPECTIVES

Send us a text What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and genetic disorders, gene therapy represents decades of persistence, innovation, and scientific courage. We explore the researchers who refused to give up, the breakthroughs that revived the field, and the biotech companies leading today’s gene therapy revolution, including pioneers developing CRISPR editing, viral vector platforms, and personalized cellular therapies. We also break down why gene therapy is reshaping the pharmaceutical industry and what the future may hold for curing previously untreatable diseases. If you love biotech, cutting-edge science, and the stories behind medical breakthroughs, this is an episode you don’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #GeneTherapy #Biotech #Genetics #CRISPR #CellTherapy #RareDisease #CancerResearch #Biopharma #MedicalInnovation #PrecisionMedicine #SciencePodcast #LifeSciences #DrugDevelopment #FutureOfMedicine #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc.  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away? In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success of Aricept, and finally the long, controversial road to Leqembi, Eisai’s journey is one of persistence, philosophy, and scientific conviction. We break down how Eisai partnered with Biogen, why leadership under Haruo Naito stayed the course when others exited neuroscience, and how a Japan-based company became a global force in CNS drug development. Along the way, we examine Eisai’s approach to risk, regulation, M&A, and what its future looks like beyond Alzheimer’s. This is a story about long-term thinking in a short-term industry and what happens when belief outlasts doubt. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin  #Eisai #Biotech #Pharma #Alzheimers #Neuroscience #DrugDevelopment #Biogen #HealthcareInnovation #PharmaHistory #LifeSciences #BiotechPodcast #ScienceAndBusiness #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his early life shaped by uncertainty to the founding of a firm that treats biology like an engineering discipline, we explore how Flagship redefined what it means to create companies from first principles. We unpack how Flagship pioneered the venture creation model, its early proximity to the MIT and Harvard ecosystem, and how relationships with the Langer lab helped give rise to Moderna long before mRNA was mainstream. We also examine how Flagship systematically identified entire sectors, from AI-driven protein design to microbiome therapeutics and sustainable agriculture, and why its biggest bets often looked unreasonable for years before paying off. Finally, we look at the people who made their mark, the lessons Flagship teaches about patience and risk in biotech, and what’s next as the firm pushes into AI-native biology and programmable medicine. If you want to understand how the future of life sciences is designed, not discovered, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #FlagshipPioneering #Biotech #VentureCreation #Moderna #NoubarAfeyan #LifeSciences #Biotechnology #StartupStories #DeepTech #HealthcareInnovation #BioEngineering #AIinBiotech #ScienceToScale Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial field long before most pharma companies dared to enter it. In this episode, we trace Biogen’s full journey, from its academic origins and the rise of interferon therapies for multiple sclerosis, to blockbuster drugs like Avonex and Tysabri. We explore the diseases Biogen chose to fight, why the company doubled down on neurology, and how its scientific culture shaped both its breakthroughs and its blind spots. We then examine Biogen’s high-stakes pivot into Alzheimer’s disease, the controversy surrounding Aduhelm, and the cautious redemption attempt with Leqembi. Along the way, we highlight the people who built Biogen, the alumni who went on to shape the biotech industry, and the hard lessons learned when science, regulation, and patient hope collide. This is a story about ambition, uncertainty, and what it really takes to develop medicines when the biology refuses to cooperate. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biogen #Biotech #Pharma #Neuroscience #Alzheimers #MultipleSclerosis #DrugDevelopment #LifeSciences #Biopharma #HealthcareInnovation #SciencePodcast #BusinessOfBiotech #MedicalResearch #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history.  In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its founding in 2003 to its dramatic collapse and criminal convictions nearly two decades later. We explore how ambition, secrecy, and Silicon Valley mythology allowed unproven science to scale into a $9 billion company, how powerful board members and investors failed to ask the right questions, and how whistleblowers and investigative journalism ultimately exposed the truth. This is a story about innovation without evidence, the dangers of charisma over data, and why medicine is uniquely unforgiving of hype. A cautionary tale at the intersection of biotech, venture capital, media, and power. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Theranos #ElizabethHolmes #Biotech #HealthcareInnovation #SiliconValley #MedicalFraud #InvestigativeJournalism #WallStreetJournal #JohnCarreyrou #VentureCapital #HealthTech #ScienceVsHype #BusinessPodcast #BiotechPodcast #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Novo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness. In this episode, we trace Novo Nordisk’s journey from the discovery of insulin and a decades-long rivalry between two Danish labs, to a landmark merger, global expansion, and steady leadership in diabetes care. We explore how the company mastered insulin manufacturing, pioneered drug delivery systems, and quietly built one of the most disciplined scientific cultures in pharma. This is a story about patience, focus, and how decades of unglamorous excellence can suddenly change the world. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #NovoNordisk #Biotech #Pharma #GLP1 #Ozempic #Wegovy #Diabetes #Obesity #Healthcare #LifeSciences #Biopharma #SciencePodcast #BusinessOfBiotech #MedicalInnovation #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for December 2025! This month was dominated by a surge in M&A activity and licensing deals. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Before there were blockbuster drugs, clinical trials, and biotech startups, there was… dye. In this episode of Petri Dish Perspectives, we explore one of the most overlooked origin stories in modern medicine: how 19th-century chemical dye companies laid the foundation for today’s pharmaceutical giants. From coal tar chemistry and synthetic pigments to the birth of industrial drug discovery, this episode unpacks why companies like Bayer, BASF, Ciba, and Hoechst evolved from coloring textiles to curing disease. We dive into the science that connects dyes and drugs, the role of wartime chemistry and national strategy, and the researchers who transformed color into cure. This is the story of how industrial chemistry reshaped medicine and why modern pharma still carries the DNA of its dye-making past. Whether you’re in biotech, pharma, or just curious about how science and history collide, this episode reveals why the pharmaceutical industry didn’t start in hospitals but in chemistry labs. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #PharmaHistory #DrugDiscovery #IndustrialChemistry #Biotechnology #Pharmaceuticals #SciencePodcast #ChemistryToCures #MedicalInnovation #BiotechEducation Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text In this episode, we explore the evolution of Astellas Pharma, from the merger of two century-old Japanese firms into a global biopharmaceutical powerhouse. We trace how a culture of disciplined research led to breakthrough medicines like Prograf, transformed transplant medicine, and later to Xtandi, a prostate cancer therapy born from academic insight and refined through global collaboration. We unpack how Astellas quietly repositioned itself toward oncology, gene therapy, and regenerative medicine while navigating the challenges of globalization, risk-taking, and long development timelines. This episode is about how long-term thinking, scientific rigor, and cultural continuity can still win in an industry driven by speed. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Astellas #Biotech #Pharma #DrugDiscovery #Oncology #PrecisionMedicine #JapanesePharma #Xtandi #TransplantMedicine #Biopharma #LifeSciences #PharmaStrategy #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text In this episode of Petri Dish Perspectives, we dive deep into the remarkable evolution of Novartis, one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making origins to its modern dominance in gene therapy, oncology, and complex biologics, Novartis has become a case study in strategic reinvention. We explore the company’s defining breakthroughs from Gleevec, the drug that rewrote the playbook for targeted cancer therapies, to cutting-edge innovations like CAR-T, RNA therapeutics, radioligand therapy, and AI-driven drug design. You’ll learn how visionary leaders, bold pipeline bets, and a focus on precision medicine shaped Novartis into a global powerhouse. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Novartis #BiotechPodcast #DrugDiscovery #Gleevec #CAR_T #GeneTherapy #OncologyInnovation #PharmaStrategy #PetriDishPerspectives #HealthcareInnovation #PrecisionMedicine #LifeSciences #BiotechResearch Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Can a machine discover a cure faster than a scientist? Welcome to the revolutionary world of Recursion Pharmaceuticals, the pioneering TechBio company determined to solve biology using AI and industrial automation. In this deep-dive, we explore how Recursion replaced slow, human-biased research with the Recursion OS, a closed-loop platform that generates massive, proprietary biological data. Learn about the company's bold vision, from the crucial $50 million NVIDIA investment and the strategic merger with Exscientia to the immense computational power of the Boltz-2 supercomputer. We analyze their pipeline progress in oncology and rare diseases, discuss the challenges of high cash burn (like the recent pipeline streamlining in November 2025), and examine their critical partnerships with giants like Roche/Genentech. Discover why Recursion is leading the charge to build the digital "Map of Biology and Chemistry" to cut drug discovery time from a decade to mere years. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Recursion #TechBio #AIDrugDiscovery #NVIDIA #Biotech #PharmaInnovation #MachineLearning #OmicsData #Genomics #RecursionOS #PetriDishPerspectives #BiotechPodcast Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for November 2025! This month was dominated by a surge in M&A activity, with high-profile bidding wars!  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text Unlock the future of immunotherapy. For decades, traditional antibody drugs were limited to tagging a single target. Now, meet the Bispecific Antibody (BsAb): a revolutionary molecule engineered to simultaneously grab two different targets, acting as a molecular "handcuff" to drag your immune system's most powerful killer, the T cell, directly to the cancer cell. In this episode, we trace the incredible scientific journey of BsAbs: from the manufacturing failure of the Quadroma Problem to the engineering solution of the "Knobs-into-Holes" strategy and the super-potent BiTE format. You'll hear how drugs like Blinatumomab have become "off-the-shelf" T-cell therapies, transforming treatment for blood cancers. We also explore the challenges of managing side effects like Cytokine Release Syndrome (CRS) and the promise of using BsAbs to conquer solid tumors. If you want to understand the sharp edge of modern cancer research, this is a must-listen. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #BispecificAntibodies #Immunotherapy #CancerResearch #BiotechBreakthrough #Oncology #TCellEngager #SciencePodcast #DrugDiscovery #PetriDishPerspectives Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

Send us a text In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk. We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin analogs, became one of the most sought-after assets in metabolic disease. You’ll learn how the bidding unfolded, what the acquisition means for obesity therapeutics, and why Pfizer ultimately paid nearly $10 billion to secure the company. If you want to understand obesity biotech, GLP-1 strategy, and how a young startup can reshape Big Pharma’s roadmap, this is the episode to hear. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Metsera #Pfizer #NovoNordisk #GLP1 #ObesityDrugs #BiotechPodcast #FlagshipPioneering #DrugDevelopment #PharmaNews #LifeSciences Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.